Secondary analysis of ERSPC Rotterdam: at 21 years, PSA screening did not lower prostate cancer mortality in men aged 55-69 with comorbidity (RR 1.09) but did in men without comorbidity (RR 0.67; 5.4 fewer deaths per 1000). No difference in men aged 70+.
Secondary analysis
Westerhout et al. Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam